Comment: renal protective effects of angiotensin receptor blockers

Abstract

Get full access to this article

View all access options for this article.

References

1. Coyle

, Gardner

, White

. The renal protective effects of angiotensin II receptor blockers in type 2 diabetes mellitus. Ann Pharmacother 2004; 38: 1731–8. DOI 10.1345/aph.1E182

2. Brenner

, Cooper

, de Zeeuw

, Keane

, Mitch

, Parving

, Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–9.

3. Lewis

, Hunsicker

, Clarke

, Berl

, Pohl

, Lewis

, for the Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 34: 851–60.

4. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998; 317: 703–13.

5. Julius

, Kjeldsen

, Weber

, Brunner

, Ekman

, Hansson

, for the VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022–31.